Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study

BACKGROUND: Microsatellite stable (MSS) colorectal cancer (CRC) has been referred to as the “cold tumor” because of almost no response to anti–programmed death-1 (PD-1) antibody. A recent REGONIVO trial showed that regorafenib plus nivolumab had an encouraging efficacy in MSS metastatic CRC (mCRC)....

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Xuan, Ding, Wenjun, He, Yongshan, Huang, Shiyong, Liu, Yun, Wu, Tingyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482431/
https://www.ncbi.nlm.nih.gov/pubmed/37681031
http://dx.doi.org/10.3389/fonc.2023.1227644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482431/
https://www.ncbi.nlm.nih.gov/pubmed/37681031
http://dx.doi.org/10.3389/fonc.2023.1227644

Ejemplares similares